Division of Roche
Latest From Ignyta Inc.
Roche's main consideration when partnering is to "access great science" regardless of location. More of this is expected to come out of Asia, its global partnering head tells Scrip.
Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.
Roche’s tumor-agnostic drug receives first approval globally in Japan following an expedited review, giving the Swiss group a lead over its rival in this market. But sales may be limited.
Lim, CEO of Ignyta when it was sold to Roche earlier this year, has moved on to the start-up Erasca with $42m in Series A venture cash to develop "precision oncology" drugs.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
Jonathan E Lim, MD, Chmn. & CEO
Jacob Chacko, MD, CFO
Zachary Hornby, COO
William McCarthy, CBO
Pratik S Multani , MD, CMO
- Contact Info
Phone: (858) 255-5959
4545 Towne Centre Ct.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.